Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.49 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CPT1A | P50416 | 1/20 | 0.42 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972236 | 0.87 | SMN1; SMN2 (0.50) | ALDH1A1POLBNPC1RAB9AKDM4E | |
| SCHEMBL3968565 | 0.83 | NR1H4 (0.67) | NR1H4HPSEALDH1A1POLBKDM4E | |
| SCHEMBL3970052 | 0.81 | ALDH1A1 (0.58) | NR1H4HPSEALDH1A1POLBNPC1 | |
| SCHEMBL963654 | 0.74 | ATM (0.54) | POLBKDM4ENLRP3ATM | |
| SCHEMBL3973956 | 0.72 | SMN1; SMN2 (0.57) | NR1H4ALDH1A1POLBNPC1RAB9A | |
| SCHEMBL3972228 | 0.71 | SMN1; SMN2 (0.56) | ALDH1A1POLBNPC1RAB9AKDM4E | |
| SCHEMBL27658312 | 0.71 | NR1H4 (0.52) | NR1H4ALDH1A1POLBNPC1RAB9A | |
| SCHEMBL30455793 | 0.71 | PGR (0.66) | ALDH1A1POLBNPC1RAB9AKDM4E | |
| SCHEMBL3972201 | 0.70 | ALDH1A1 (0.53) | HPSEALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL11739989 | 0.69 | PTGS1 (0.66) | NR1H4HPSEALDH1A1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569602-B2 | Furan derivatives as EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-7569602-B2 | Furan derivatives as EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-7569602-B2 | Furan derivatives as EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| EP-1673360-B1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| EP-1673360-B1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-7417068-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-08-26 | — | — | US | disclosed |
| US-7417068-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-08-26 | — | — | US | disclosed |
| US-7417068-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-08-26 | — | — | US | disclosed |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1673360-A1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2006-06-28 | — | — | EP | disclosed |
| US-20050124676-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2005-06-09 | — | — | US | disclosed |
| WO-2005037812-A1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124676-A1 | EP4 receptor antagonists | PTGER4, PTGER3, NR4A3 | NR1H4 231/4885HPSE 4153/4885ALDH1A1 2257/4885 |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER3, NR4A3 | NR1H4 231/4885HPSE 4153/4885ALDH1A1 2257/4885 |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | PTGER4, PTGER3, NR4A3 | NR1H4 322/4885HPSE 4046/4885ALDH1A1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.